Recent Press Releases

Technical Report on Biotech Stocks -- MannKind, Amgen, Celldex Therapeutics, Juno Therapeutics, and Ironwood Pharma

Editor Note: For more information about this release, please scroll to bottom.

LONDON, December 31, 2014

OncoGenex to Regain Rights to Custirsen from Teva

BOTHELL Wash. and VANCOUVER, British Columbia, Dec.

U.S. Food and Drug Administration Approves KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation

--Approximately 500 people with cystic fibrosis ages 6 and older have the R117H mutation in the United States-- BOSTON, Dec 29, 2014 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated VRTX,...

Technical Commentary on Pharma Stocks -- AstraZeneca, Horizon Pharma, Valeant Pharma Intl., Exact Sciences, and Novo Nordisk

Editor Note: For more information about this release, please scroll to bottom.

LONDON, December 29, 2014

FDA APPROVES GAZYVA® (OBINUTUZUMAB) SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION WITH NEW DATA IN PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA

FDA APPROVES GAZYVA® (OBINUTUZUMAB) SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION WITH NEW DATA IN PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA South San Francisco, Calif. – December 24,...

Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension

DUBLIN, Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New...

Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride

- Indicated for Treatment of Moderate to Severe Alzheimer's Disease - DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc....

Use of Composites in Orthopedic Industry to Reach $596 Million by 2020

NEW YORK and LONDON, December 24, 2014 /PRNewswire/ --

Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta

Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta SAN DIEGO, Dec 22, 2014 (BUSINESS WIRE) -- Ligand Pharmaceuticals Incorporated LGND,...

United States Files Suit Against Omnicare Inc. for Accepting Kickbacks from Drug Manufacturer to Promote an Anti-Epileptic Drug in Nursing Homes

The United States has filed a civil False Claims Act complaint against Omnicare Inc. alleging that it solicited and received millions of dollars in kickbacks from pharmaceutical manufacturer Abbott...

Lilly Announces Diabetes Research Partnership with University of Surrey

The five-year collaboration with the UK public research university will focus on health outcomes for people with type 2 diabetes

INDIANAP

Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts

Sponsorship Secures Resources Needed for Biotech Startups to Advance Innovative Research

CAMBRIDGE, Mass.,

Abbott Completes Acquisition of Topera, Inc.

ABBOTT PARK, Ill., Dec.

Cubist Announces FDA Approval of New Antibiotic ZERBAXA(TM) (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections

ZERBAXA addresses certain serious and resistant Gram-negative bacteria First new antibiotic approved in U.S. under the GAIN Act that treats Gram-negative bacteria LEXINGTON, Mass. - (Business...

FDA approves Lynparza to treat advanced ovarian cancer

The U.S. Food and Drug Administration today granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as...

LYNPARZA™ APPROVED BY THE US FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF ADVANCED OVARIAN CANCER IN PATIENTS WITH GERMLINE BRCA-MUTATIONS

19 December 2014 AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved LYNPARZA™ (olaparib) capsules (400mg twice daily) as the first monotherapy for patients...

Bina Technologies is acquired by Roche.

REDWOOD CITY, Calif., Dec. 19, 2014 /PRNewswire/ -- Bina Technologies, Inc.

Teva Announces FDA Approval of QNASL® (Beclomethasone Dipropionate) Nasal Aerosol for Treatment of Children with Seasonal and Perennial Allergic Rhinitis

First Waterless Nasal Allergy Spray Approved for Children as Young as Four Years of Age JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (TEVJF), (NYSE:TEVA) announced today that the...